<?xml version="1.0" encoding="UTF-8"?>
<ref id="B83-pharmaceuticals-12-00101">
 <label>83.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ren</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Zou</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Bailly</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Zeng</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Chen</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Shen</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Guillon</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Arenzana-Seisdedos</surname>
    <given-names>F.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection-suramin inhibits EV71 infection in vitro and in vivo</article-title>
  <source>Emerg. Microbes Infect.</source>
  <year>2014</year>
  <volume>3</volume>
  <fpage>e62</fpage>
  <pub-id pub-id-type="doi">10.1038/emi.2014.60</pub-id>
  <?supplied-pmid 26038755?>
  <pub-id pub-id-type="pmid">26038755</pub-id>
 </element-citation>
</ref>
